One percent of U.S. cancer doctors, many with leadership roles in hospitals, academia, national health institutes, and guideline-making, received over $24 million in payments from cancer pharmaceutical companies in 2018, according to a new study by Queen’s University in Canada.
The study found that 139 oncologists—representing 1 percent of all American cancer doctors—were given over $100,000 in general payments, with a median payment of around $154,000, and a total of $24.2 million.
“A payment of this magnitude creates a high risk” of conflict of interest, the authors wrote in the study, with $10,000 considered to be a significant payment by the U.S. Department of Health and Human Services….